Bernstein raised the firm’s price target on Elevance Health (ELV) to $585 from $511 and keeps an Outperform rating on the shares. The firm sees it as benefiting from expected recovery in government managed care margins, an expected deceleration of utilization as it normalizes post-COVID, and historically low valuations.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Positive Outlook for Elevance Health: Buy Rating Driven by Recovery in Government-Managed Care Margins and Low Valuation Levels
- Health insurers received duplicate payments for Medicaid patients, WSJ reports
- Elevance Health upgraded to Buy from Hold at Argus
- Dr. Oz says would address ‘upcoding,’ Fierce Healthcare reports
- Oz grilled at Senate confirmation hearing, NY Times reports